Eli Lilly and Company (NYSE:LLY) Stock Holdings Increased by Magnus Financial Group LLC

Magnus Financial Group LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,418 shares of the company’s stock after purchasing an additional 163 shares during the quarter. Magnus Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,158,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Convergence Investment Partners LLC boosted its stake in Eli Lilly and Company by 9.5% in the 4th quarter. Convergence Investment Partners LLC now owns 1,554 shares of the company’s stock worth $906,000 after purchasing an additional 135 shares during the period. Little House Capital LLC raised its position in Eli Lilly and Company by 85.3% during the fourth quarter. Little House Capital LLC now owns 2,515 shares of the company’s stock valued at $1,466,000 after buying an additional 1,158 shares during the period. Kapstone Financial Advisors LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $292,000. Stonebrook Private Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $1,493,000. Finally, Pitti Group Wealth Management LLC grew its stake in Eli Lilly and Company by 292.2% during the 4th quarter. Pitti Group Wealth Management LLC now owns 1,659 shares of the company’s stock valued at $967,000 after acquiring an additional 1,236 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Up 1.2 %

Shares of LLY stock traded up $8.64 on Friday, hitting $733.51. 2,009,249 shares of the stock were exchanged, compared to its average volume of 2,265,427. The business has a 50-day moving average of $761.79 and a 200 day moving average of $666.67. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78. The firm has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the business earned $2.09 EPS. Equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.